Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according ...

The impact that Bernie Williams’ father had on him was immeasurable. Without the sage advice and caring personality of ...

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

The U.S. Food and Drug Administration said on Friday it has approved Boehringer Ingelheim's drug for patients with a type of ...

Rheumatoid arthritis (RA) commonly causes joint damage and fatigue, but it may sometimes cause symptoms that affect your skin ...

Baron Capital highlights biotech and robotic surgery as key growth drivers in Q2. See which stocks surged, which stumbled, ...

Added to Russell 3000® Index: In June 2025, Tectonic was added to the Russell 3000® Index as part of FTSE Russell’s annual reconstitution. Inclusion in the index broadens the company’s exposure to ...